SCHEMBL4617855

SCHEMBL4617855

NS(=O)(=O)c1cccc(S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.74
CA1 P00915 10/20 0.74
CA9 Q16790 8/20 0.62
CA12 O43570 7/20 0.62
CA14 Q9ULX7 3/20 0.62
CA13 Q8N1Q1 3/20 0.62
CA7 P43166 3/20 0.62
CA4 P22748 2/20 0.62
CA5A P35218 2/20 0.62
CA3 P07451 1/20 0.62
CA6 P23280 1/20 0.62
PLA2G7 Q13093 1/20 0.62
CA5B Q9Y2D0 1/20 0.62
HTR6 P50406 2/20 0.61
LMNA P02545 3/20 0.54
ALDH1A1 P00352 2/20 0.53
THRB P10828 1/20 0.53
TSHR P16473 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6541920 0.93 CA2 (0.85) CA2CA1CA9CA12CA14
SCHEMBL9140147 0.89 HTR6 (0.78) CA2CA1CA9CA12CA14
SCHEMBL28709181 0.89 HTR6 (0.78) CA2CA1CA9CA12CA14
SCHEMBL2398133 0.86 CA2 (1.00) CA2CA1CA9CA12CA14
SCHEMBL10691065 0.84 CA2 (0.80) CA2CA1CA9CA12CA14
SCHEMBL1332008 0.81 HTR6 (0.82) CA2CA1CA9CA12CA14
SCHEMBL487472 0.78 LMNA (0.87) CA2CA1CA9CA12CA14
SCHEMBL1926937 0.78 CA2 (0.67) CA2CA1CA9CA12CA14
SCHEMBL415483 0.78 SMN1; SMN2 (0.62) HTR6LMNAALDH1A1THRBTSHR
SCHEMBL31540998 0.78 SMN1; SMN2 (0.62) HTR6LMNAALDH1A1THRBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 CA2 2749/4885CA1 1450/4885CA9 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.